[go: up one dir, main page]

WO2010020766A3 - Interleukin fusion polypeptides - Google Patents

Interleukin fusion polypeptides Download PDF

Info

Publication number
WO2010020766A3
WO2010020766A3 PCT/GB2009/002004 GB2009002004W WO2010020766A3 WO 2010020766 A3 WO2010020766 A3 WO 2010020766A3 GB 2009002004 W GB2009002004 W GB 2009002004W WO 2010020766 A3 WO2010020766 A3 WO 2010020766A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptides
polypeptides
interleukin fusion
interleukin
dimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/002004
Other languages
French (fr)
Other versions
WO2010020766A2 (en
Inventor
Peter Artymiuk
Richard Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asterion Ltd
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Publication of WO2010020766A2 publication Critical patent/WO2010020766A2/en
Publication of WO2010020766A3 publication Critical patent/WO2010020766A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure relates to interleukin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.
PCT/GB2009/002004 2008-08-21 2009-08-17 Interleukin fusion polypeptides Ceased WO2010020766A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9082508P 2008-08-21 2008-08-21
GB0815216.7 2008-08-21
GB0815216A GB0815216D0 (en) 2008-08-21 2008-08-21 Interleukin
US61/090,825 2008-08-21

Publications (2)

Publication Number Publication Date
WO2010020766A2 WO2010020766A2 (en) 2010-02-25
WO2010020766A3 true WO2010020766A3 (en) 2010-07-29

Family

ID=39812328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002004 Ceased WO2010020766A2 (en) 2008-08-21 2009-08-17 Interleukin fusion polypeptides

Country Status (2)

Country Link
GB (1) GB0815216D0 (en)
WO (1) WO2010020766A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2013074489A1 (en) 2011-11-14 2013-05-23 Emory University Conjugates of gm-csf and il-7, compositions and methods related thereto
WO2013184938A2 (en) * 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
MA40094B1 (en) * 2014-08-06 2022-05-31 Univ Miami Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
CN109689694B (en) * 2016-05-19 2022-11-22 通用医疗公司 IL2 binding to its receptor IL-2R beta as a platform to enhance natural killer and regulatory T cell activity
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag Antibody IL2 engrafted proteins and methods of use in the treatment of cancer”
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US11359000B2 (en) * 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
MX2020012252A (en) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of use thereof.
CN113840832A (en) 2018-05-14 2021-12-24 狼人治疗公司 Activatable interleukin-2 polypeptides and methods of using the same
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION CHARACTERISTIC GROUPS, ASSOCIATED PROCESSES AND USE
CN114450297A (en) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 IL-2 compositions and methods of use thereof
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023512456A (en) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Methods of treating tumors with a combination of IL-7 protein and bispecific antibody
KR20220137630A (en) 2020-02-05 2022-10-12 워싱턴 유니버시티 Method of treating solid tumors with a combination of IL-7 protein and CAR-bearing immune cells
KR20230098201A (en) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 Methods of inducing stem cell mobilization
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (en) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド How to treat tumors with a combination of IL-7 protein and nucleotide vaccines
AU2022241762A1 (en) 2021-03-24 2023-09-14 Mural Oncology, Inc. Upar antibodies and fusion proteins with the same
TW202317623A (en) * 2021-06-14 2023-05-01 美商再生元醫藥公司 Il2-based therapeutics and methods of use thereof
WO2023121254A1 (en) * 2021-12-20 2023-06-29 한양대학교 산학협력단 Interleukin-2 fusion protein, method for preparing same, and pharmaceutical composition comprising same
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2025021144A1 (en) * 2023-07-25 2025-01-30 TJ Biopharma (Shanghai) Co., Ltd. Masked interferon fusion proteins and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032141A1 (en) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Ifnar2/ifn complex
WO2003059376A1 (en) * 2001-12-31 2003-07-24 Yeda Research And Development Co. Ltd. The use of il6r/il6 chimera in nerve cell regeneration
WO2006061219A2 (en) * 2004-12-09 2006-06-15 Merck Patent Gmbh Il-7 variants with reduced immunogenicity
WO2009019456A1 (en) * 2007-08-08 2009-02-12 Asterion Limited Interferon fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032141A1 (en) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Ifnar2/ifn complex
WO2003059376A1 (en) * 2001-12-31 2003-07-24 Yeda Research And Development Co. Ltd. The use of il6r/il6 chimera in nerve cell regeneration
WO2006061219A2 (en) * 2004-12-09 2006-06-15 Merck Patent Gmbh Il-7 variants with reduced immunogenicity
WO2009019456A1 (en) * 2007-08-08 2009-02-12 Asterion Limited Interferon fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALMER MEGAN J ET AL: "Interleukin-7 receptor signaling network: An integrated systems perspective", April 2008, CELLULAR & MOLECULAR IMMUNOLOGY, VOL. 5, NR. 2, PAGE(S) 79-89, ISSN: 1672-7681, XP002566080 *
VALERIO A ET AL: "SOLUBLE INTERLEUKIN-6 (IL-6) RECEPTOR/IL-6 FUSION PROTEIN ENHANCES IN VITRO DIFFERENTIATION OF PURIFIED RAT OLIGODENDROGLIAL LINEAGE CELLS", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 21, 1 January 2002 (2002-01-01), pages 602 - 615, XP001208544, ISSN: 1044-7431 *
WILKINSON IAN R ET AL: "A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 9, 1 September 2007 (2007-09-01), pages 1108 - 1113, XP009089546, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2010020766A2 (en) 2010-02-25
GB0815216D0 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
WO2010020766A3 (en) Interleukin fusion polypeptides
ZA202308845B (en) Cx3cr1-binding polypeptides
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
GB201020995D0 (en) Biological materials and uses thereof
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
WO2011063308A3 (en) Beta-glucosidase variants with improved properties
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MX349630B (en) Alpha-amylases.
WO2012109373A3 (en) Treatment of osteoarthritis and pain
SI3536703T1 (en) Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2011039368A3 (en) Dll4-binding molecules
EA201390666A1 (en) CXCR2-BONDING POLYPEPTIDES
HK1213194A1 (en) Novel binding proteins for pcsk9
WO2009019441A3 (en) Granulocyte colony stimulating factor
WO2011017330A8 (en) Concentrated polypeptide formulations with reduced viscosity
WO2010001134A3 (en) Insulin fusion polypeptides
WO2012031137A3 (en) Vesicular stomatitis viruses
EP2270145A4 (en) Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
WO2013040517A3 (en) IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
WO2010108182A3 (en) Production of recombinant proteins in ciliates and uses thereof
WO2011011630A3 (en) Nitrilase biocatalysts
WO2010040736A3 (en) Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2008106662A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09784942

Country of ref document: EP

Kind code of ref document: A2